We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

63 hedge funds and large institutions have $155M invested in OncoMed Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 10

73% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 11

15% more funds holding

Funds holding: 5563 (+8)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

23% less capital invested

Capital invested by funds: $200M → $155M (-$45.3M)

Holders
63
Holders Change
+8
Holders Change %
+14.55%
% of All Funds
1.81%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
19
Increased
29
Reduced
10
Closed
11
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$854K +$142K +5,760 +19%
BIM
27
BlackRock Investment Management
Delaware
$841K +$558K +22,598 +167%
CIP
28
Convergence Investment Partners
Florida
$669K +$709K +28,715 New
GT
29
Glenmede Trust
Pennsylvania
$668K
CS
30
Credit Suisse
Switzerland
$612K +$340K +13,757 +110%
ProShare Advisors
31
ProShare Advisors
Maryland
$562K -$78.1K -3,162 -12%
California State Teachers Retirement System (CalSTRS)
32
California State Teachers Retirement System (CalSTRS)
California
$538K +$360K +14,600 +172%
Charles Schwab
33
Charles Schwab
California
$531K +$252K +10,220 +81%
JP Morgan Chase
34
JP Morgan Chase
New York
$529K +$561K +22,714 New
TA
35
Teachers Advisors
New York
$410K +$277K +11,206 +175%
HCM
36
Hodges Capital Management
Texas
$349K
Bank of Montreal
37
Bank of Montreal
Ontario, Canada
$306K +$52.3K +2,120 +19%
Jane Street
38
Jane Street
New York
$299K +$317K +12,820 New
Millennium Management
39
Millennium Management
New York
$266K -$429K -17,360 -60%
RFC
40
Russell Frank Company
Washington
$263K -$365K -14,765 -56%
BA
41
BlackRock Advisors
Delaware
$259K +$188K +7,607 +218%
AIG
42
American International Group
New York
$258K +$112K +4,527 +69%
MLICM
43
Metropolitan Life Insurance Company (MetLife)
New York
$239K +$254K +10,270 New
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$231K +$245K +9,930 New
NFA
45
Nationwide Fund Advisors
Ohio
$224K +$148K +5,991 +165%
Citigroup
46
Citigroup
New York
$211K +$150K +6,066 +204%
Manulife (Manufacturers Life Insurance)
47
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$205K +$111K +4,504 +105%
VOYA Investment Management
48
VOYA Investment Management
Georgia
$202K +$214K +8,652 New
Swiss National Bank
49
Swiss National Bank
Switzerland
$175K +$185K +7,500 New
Barclays
50
Barclays
United Kingdom
$165K +$49.6K +2,008 +39%

OMED Hedge Fund Activity: Q2 2014 in Review

63 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2014, worth a combined $155M — down 23% from $200M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new OMED positions and 11 closed out — a net gain of 8 holders — while 29 added to existing stakes and 10 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $16.3M. The largest seller was Columbus Circle Investors, cutting an estimated $10.9M.

  • 63 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2014, up from 55 in Q1 2014.
  • Funds reported $155M of OncoMed Pharmaceuticals, Inc. stock for Q2 2014, down 23% quarter-over-quarter.
  • 19 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2014 and 11 closed out, a net change of +8 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q2 2014 was Fidelity Investments, an estimated $16.3M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2014 was Columbus Circle Investors, an estimated $10.9M sold.

Based on aggregated 13F filings for Q2 2014.